Phase II trial of docetaxel therapy in patients with advanced hepatocellular carcinoma.

@article{Hebbar2006PhaseIT,
  title={Phase II trial of docetaxel therapy in patients with advanced hepatocellular carcinoma.},
  author={Mohamed Hebbar and Olivier Ernst and St{\'e}phane Cattan and Sophie Dominguez and Corina Oprea and Philippe Mathurin and J. -P. Triboulet and J. Paris and F R Pruvot},
  journal={Oncology},
  year={2006},
  volume={70 2},
  pages={154-8}
}
OBJECTIVES We assessed the safety and efficacy of docetaxel, a microtubule inhibitor, in patients with advanced hepatocellular carcinoma (HCC). METHODS HCC patients that were not suitable for local therapy, but who possessed measurable disease, good performance status and adequate organ function were eligible. Docetaxel was administered every 3 weeks at a dose of 100 mg/m(2) (or 75 mg/m(2) if transaminase levels were between 1.5 and 3.5 times the upper normal limit). Efficacy was assessed… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 15 extracted citations

Similar Papers

Loading similar papers…